Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.

Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.

Overexpression or/and activating mutation of FLT3 kinase play a major driving role in the pathogenesis of acute myeloid leukemia (AML). Hence, pharmacologic inhibitors of FLT3 are of therapeutic potential for AML treatment. In this study, BPR1J-340 was identified as a novel potent FLT3 inhibitor by...

Full description

Bibliographic Details
Main Authors: Wen-Hsing Lin, Teng-Kuang Yeh, Weir-Torn Jiaang, Kuei-Jung Yen, Chun-Hwa Chen, Chin-Ting Huang, Shih-Chieh Yen, Shu-Yi Hsieh, Ling-Hui Chou, Ching-Ping Chen, Chun-Hsien Chiu, Li-Chun Kao, Yu-Sheng Chao, Chiung-Tong Chen, John T-A Hsu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3885398?pdf=render

Internet

http://europepmc.org/articles/PMC3885398?pdf=render

Similar Items